The “Saatchi bill” will allow responsible innovation in treatment
BMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g2771 (Published 15 April 2014) Cite this as: BMJ 2014;348:g2771All rapid responses
Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web address) of an individual response, simply click on the response headline and copy the URL from the browser window. A proportion of responses will, after editing, be published online and in the print journal as letters, which are indexed in PubMed. Rapid responses are not indexed in PubMed and they are not journal articles. The BMJ reserves the right to remove responses which are being wilfully misrepresented as published articles or when it is brought to our attention that a response spreads misinformation.
From March 2022, the word limit for rapid responses will be 600 words not including references and author details. We will no longer post responses that exceed this limit.
The word limit for letters selected from posted responses remains 300 words.
In his discussion of the Medical Innovation Bill, Michael Rawlins [1] refers to Judge Butler-Sloss’s forceful criticism of the Bolam principle while she was president of the High Court’s Family Division because it leaves doctors open to legal action for negligence if they depart from what is regarded as “the standard of care”. We have direct experience of the adverse consequence of an important omission from Judge Butler-Sloss’s judgement.
We co-chaired the MRC Prion-1 trial steering committee at the time (17 Dec 2002) that the father of a young man with variant Creutzfeld-Jakob Disease (vCJD) appealed to the High Court for permission to seek treatment for his son using pentosan polysulphate injected into the brain. The father believed that the drug might slow his son’s decline because it appeared to have done this in an animal model of the disease studied in Japan. Judge Butler-Sloss granted permission for the father to seek treatment for his son [2], and similar judgements were made subsequently in respect of other sufferers of vCJD.
In making her ruling Judge Butler-Sloss suggested that treatment with penicillin might never have been attempted if the Bolam principle had been applied. What she failed to do was to require organised, prospective documentation and publication of the characteristics and progress of patients receiving pentosan polysulphate for vCJD, as had happened with the first series of cases treated with the penicillin [3]. The consequence of this important omission from her judgement has been that patients, their parents, and the people involved in the PRION 1 trial and other related research remained and remain unnecessarily ignorant about the possible benefits and harms of this proposed treatment.
This unsatisfactory state of affairs cannot be allowed to be a feature of any treatments that may become available under the provisions of the Medical Innovation Bill. Rawlins [1] notes that, ‘just because a particular intervention seems to have been effective in an individual patient it cannot be assumed that the results are generalisable’. We regret that he did not go on to call for proper, publicly available documentation to inform decisions made by other patients and those caring for them. Failure to make such evidence accessible was one of the factors that led to the TGN 1412 disaster [4].
Lester Firkins
Iain Chalmers
Co-chairs, MRC Prion 1 trial steering committee
[1] Rawlins MD. “Saatchi Bill” will encourage innovation in treatment. BMJ 2014;348:13.
[2] CJD case: the judgement. BBC News. http://news.bbc.co.uk/1/hi/health/2585049.stm
[3] Abraham EP, Chain E, Fletcher CM, Gardner AD, Heatley NG, Jennings AM, Florey HW. Further observations on penicillin. Lancet 1941;2:177-189.
[4] Chalmers I. TGN1412 and The Lancet’s solicitation of reports of phase 1 trials. Lancet 2006;368:2206-2207.
Competing interests: No competing interests
It is important to record that Sir Michael's understanding of the judgment of Lady Butler-Sloss (not "Butler-Schloss") in the case of Simms, is wrong. Far from holding that the Bolam test obstructed innovative treatment, she held that it supported it.
This was not a clinical negligence case. The Court had to decide whether previously untried treatment should be given to two patients suffering from vCJD (this was in 2002). At paragraph 51 of her judgment she held that, "I am satisfied, consistent with the philosophy that underpins the 'Bolam test', that there is a responsible body of relevant professional opinion which supports this innovative treatment."
Thus the Bolam test did not prevent the use of the proposed, previously untried treatment but was a check against the use of irresponsible or capriciously experimental treatment.
Competing interests: I am a clinical negligence lawyer
Saatchi law: Legal hurdles and Clinical irrelevance
The ‘Saatchi law’ is a wonderful legal initiative but it is unlikely to achieve its original aim of promoting innovative treatments. [1].
Firstly, on the legal front, it is likely to run afoul of the EU clinical trials directive, which in turn has been singularly responsible for the significant drop in number of academic clinical trials across Europe [2][3].
Secondly, there is a high failure rate in development of novel, innovative treatments. It has been estimated that only ‘’1 in 1,000 new compounds that enter preclinical testing ever make it to human testing and only 1 in 5 agents that enter human trials receive FDA approval’’. [4]. The high failure rate is not due to any legal or financial hurdles. It is just a sad fact that most novel drugs are not good enough to be used clinically. So it is indeed extremely unlikely that the proposed Saatchi law would promote new treatments. Even worse, it could end up potentially harming lot of patients by promoting use of ineffective new medications. In fact, the law could even be used to promote quackery and unscrupulous people have certainly used the legal loopholes to enrich themselves in the past. [5].
Hence, unlicensed medications, however innovative they are, should be properly tested in clinical trials (phase1, 2, & 3) to ensure scientifically credible information is obtained regarding their safety and efficacy. Clinical trials, with their ethical oversight and peer review process, should remain the gold standard, at present, for assessing novel and innovative treatments.
Thirdly, there is an important distinction between licensed and unlicensed medications. Licensed treatments are likely to have good safety data and hence use of licensed treatments for unlicensed conditions is certainly less risky. Indeed most pediatricians and many oncologists would attest that there is no clinical impediment in using licensed medications for unlicensed conditions, although in practice there is a financial impediment.
Clinically, at best, the proposed Saatchi law is likely be irrelevant but, at worst, the well intentioned legal safe guards proposed in the law would paradoxically end up curtailing the current widespread use of licensed medications for unlicensed conditions.
References:
1 Rawlins MD. The ‘Saatchi bill’ will allow responsible innovation in treatment. BMJ 2014;348:g2771–g2771. doi:10.1136/bmj.g2771
2 Sundar S. The law of unintended consequences. J R Soc Med 2013;106:303. doi:10.1177/0141076813496235
3 Gulland A. Number of global clinical trials done in UK fell by two thirds after EU directive. BMJ 2009;338:b1052.
4 Boklan J. Little patients, losing patience: pediatric cancer drug development. Mol Cancer Ther 2006;5:1905–8. doi:10.1158/1535-7163.MCT-06-0179
5 Holland JF. The krebiozen story. Is cancer quackery dead? Jama J Am Med Assoc 1967;200:213–8.
Competing interests: No competing interests
This Bill is unnecessary, mis-targeted and will put vulnerable patients at risk.
Current clinical negligence law does not require adherence to standard treatment. It allows innovative treatment provided it would be supported a responsible body of medical opinion, even if others would not support it.
This Bill provides a defence for doctors whose treatment causes harm to patients even where no other doctor would support the treatment. That is the central provision of the Bill and it is one which will have widespread consequences well beyond the issue of medical innovation. The Bill only requires that the doctor in question should go through various procedural steps before deciding on the treatment. There is no requirement that other professionals must endorse the decision taken.
This defence would apply to any decisions to treat which would currently be regarded in law as negligent, whether innovative or otherwise. There is no definition of "innovative treatment" within the Bill.
The Bill has nothing to say about the funding or regulation of innovative treatment.
Surely there are better ways of promoting responsible innovation than by removing the right of redress to patients who are harmed as a result of treatment which no responsible body of doctors would support?
Competing interests: I am a barrister practising in clinical negligence law
It is important to distinguish the legal principles from the consequences of professional misinterpretation of them. Elizabeth Butler-Sloss was clear in the case cited that all that the law needed was evidence "that there is a responsible body of relevant professional opinion which supports this innovative treatment." In law, the Bill may raise the barriers to innovation by imposing significantly greater procedural requirements than the current legal test. However, if clinicians perceive there to be a problem, then there is one (although not one of legal doctrine).
Competing interests: Also Chair, Health Research Authority but writing in a personal capacity here.
Re: The “Saatchi bill” will allow responsible innovation in treatment
The rapid responses from several lawyers, claiming that the provisions of the Saatchi Bill are unnecessary, underpin its relevance and importance. Other lawyers who have been consulted by Lord Saatchi take a very different view. The Saatchi Bill would therefore at least clarify the legal position for doctors, NHS Trusts and - pace the legal profession - lawyers.
The Bill would not in any way discourage clinical research and I, of all people, would not be lending it my support if it did so. Indeed, Section 2 (8b) states: "Nothing in this Section permits a doctor to carry out treatment for the purposes of reserach or for any purpose other than the patient's best interests".
As far as the point made by my old friends Lester Ferkins and Iain Chalmers, I despair! They take me to task for failing to call for "publicly available documentation" of the effects of intervening in the manner described in the Bill. They seem to have failed to notice that I made this point in the last paragraph of my paper!
Michael Rawlins
Competing interests: No competing interests